Search results
Added:
1 year ago
Added:
1 year ago
AHA 2023 — Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews investigator, Dr Jeff Healey (McMaster University, CA) to outline the findings from a phase 4 trial of apixaban to reduce thromboembolism in patients with subclinical atrial fibrillation (AF).ARTESiA (NCT01938248) aims to determine if apixaban in combination with aspirin can reduce the instance of…
View more
Added:
1 year ago
Added:
4 months ago
What updates do ECAS recommend for catheter ablation of atrial fibrillation?In this short interview, Prof Riccardo Cappato (IRCCS Humanitas Research Hospital, Milan, IT) and Prof Rui Providência (St Bartholomew's Hospital, London, UK) discuss new guidelines released by ECAS on catheter ablation for atrial fibrillation (AF). Prof Cappato and Prof Providência explain the need for an updated and…
View more
Added:
10 months ago
ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.We are joined onsite at ESC Congress 2024 by Dr Renato Lopes (Duke University Medical Center, NC) to discuss the findings from the GUARD-AF Trial (NCT04126486, Bristol-Myers Squibb), which was designed to determine if screening for undiagnosed…
View more
Added:
10 months ago
ESC Congress 2024 — OCEANIC-AF was halted early due to a lack of efficacy in 2023. Investigators shared details of the trial at ESC, comparing asundexian against apixaban in patients with atrial fibrillation at risk of stroke.Host Dr Harriette Van Spall (McMaster University, Hamilton, Canada) sits down with primary investigator Dr Manesh R Patel (Duke University Health System, USA) to discuss the…
View more
Added:
1 year ago
HRS 2024 — Prof Isabel Deisenhofer (German Heart Center Munich, Technical University of Munich, DE), investigator, joins us to discuss the findings from the TAILORED-AF trial (NCT04702451, Volta Medical).This randomised controlled trial compared a tailored ablation strategy targeting areas of patio-temporal dispersion in combination with pulmonary vein isolation (PVI) to anatomical ablation…
View more
Added:
1 year ago
EHRA 24 - Investigator, Dr William McIntyre (Population Health Research Institute, CA) joins us to discuss the findings from a substudy of ARTESiA (NCT01938248).ARTESiA was a randomized, parallel assignment clinical trial which aimed to assess if apixaban could reduce the risk of ischemic stroke and systemic embolism in patients with subclinical atrial fibrillation (AF) and additional risk…
View more
Added:
2 years ago
Dr Else Sandset (Oslo University Hospital, NO) is joined by Prof Jesse Dawson (University of Glasgow, GB), Dr Urs Fischer (University Hospital Basel, CH) and Dr Masatoshi Koga (National Cerebral and Cardiovascular Center, JP) to discuss the findings from their recent paper on "Early versus Later Anticoagulation for Stroke with Atrial Fibrillation" published in the New England Journal of Medicine…
View more
Added:
5 months ago